Skip to content
OpenCapital
Get started

Integra LifeSciences IART Operating Lease Liability Payments - 2026 (Lessee)

Operating Lease Liability Payments - 2026 (Lessee) at other companies

ICU Medical logo
ICU MedicalICUI
$7.76M-13.0%
Henry Schein logo
Henry ScheinHSIC
$59M+5.4%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's operating lease liability payments - 2026 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's operating lease liability payments - 2026 (lessee)?
Integra LifeSciences (IART) reported operating lease liability payments - 2026 (lessee) of $19.01M in Q1 2026.
How has Integra LifeSciences's operating lease liability payments - 2026 (lessee) changed year-over-year?
Integra LifeSciences's operating lease liability payments - 2026 (lessee) increased by 8.5% year-over-year, from $17.53M to $19.01M.
What does operating lease liability payments - 2026 (lessee) mean?
This represents the specific cash outflow commitment for operating leases scheduled for the calendar year 2026. It allows investors to isolate the impact of real estate and equipment lease obligations on the company's cash flow in a specific future period.